ALTO-100

Product

Last mentioned: Mar 24, 2026

Timeline

  1. Expected Data Readouts

    Anticipated primary endpoint results for the ALTO-100 Phase 2b/3 study in MDD.

  2. $120M Private Placement

    CFO Nick Smith announces a major financing round to accelerate late-stage clinical programs.

  3. Phase 2b Expansion

    Company expands clinical trials for ALTO-100 targeting specific biotypes of depression.

  4. Initial Public Offering

    Alto Neuroscience goes public on the NYSE to fund its precision psychiatry platform.

Stories mentioning ALTO-100 1

funding Bullish

Alto Neuroscience Secures $120M to Advance Precision Psychiatry Pipeline

Alto Neuroscience has successfully raised $120 million through a private placement financing to accelerate its clinical-stage pipeline of precision medicines for mental health. Led by CFO Nick Smith, the funding underscores investor confidence in the company's AI-driven approach to identifying biomarkers for psychiatric disorders.

3 sources